000118733 001__ 118733
000118733 005__ 20240319081024.0
000118733 0247_ $$2doi$$a10.3389/fimmu.2022.896228
000118733 0248_ $$2sideral$$a129673
000118733 037__ $$aART-2022-129673
000118733 041__ $$aeng
000118733 100__ $$0(orcid)0000-0002-3888-7036$$aRamírez-Labrada, Ariel
000118733 245__ $$aAll about (nk cell-mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity
000118733 260__ $$c2022
000118733 5060_ $$aAccess copy available to the general public$$fUnrestricted
000118733 5203_ $$aNK cells are key mediators of immune cell-mediated cytotoxicity toward infected and transformed cells, being one of the main executors of cell death in the immune system. NK cells recognize target cells through an array of inhibitory and activating receptors for endogenous or exogenous pathogen-derived ligands, which together with adhesion molecules form a structure known as immunological synapse that regulates NK cell effector functions. The main and best characterized mechanisms involved in NK cell-mediated cytotoxicity are the granule exocytosis pathway (perforin/granzymes) and the expression of death ligands. These pathways are recognized as activators of different cell death programmes on the target cells leading to their destruction. However, most studies analyzing these pathways have used pure recombinant or native proteins instead of intact NK cells and, thus, extrapolation of the results to NK cell-mediated cell death might be difficult. Specially, since the activation of granule exocytosis and/or death ligands during NK cell-mediated elimination of target cells might be influenced by the stimulus received from target cells and other microenvironment components, which might affect the cell death pathways activated on target cells. Here we will review and discuss the available experimental evidence on how NK cells kill target cells, with a special focus on the different cell death modalities that have been found to be activated during NK cell-mediated cytotoxicity; including apoptosis and more inflammatory pathways like necroptosis and pyroptosis. In light of this new evidence, we will develop the new concept of cell death induced by NK cells as a new regulatory mechanism linking innate immune response with the activation of tumour adaptive T cell responses, which might be the initiating stimulus that trigger the cancer-immunity cycle. The use of the different cell death pathways and the modulation of the tumour cell molecular machinery regulating them might affect not only tumour cell elimination by NK cells but, in addition, the generation of T cell responses against the tumour that would contribute to efficient tumour elimination and generate cancer immune memory preventing potential recurrences.
000118733 536__ $$9info:eu-repo/grantAgreement/ES/AEI/PID2020-113963RB-I00$$9info:eu-repo/grantAgreement/ES/DGA/B29-20R$$9info:eu-repo/grantAgreement/ES/MCIU-AEI/SAF2017-83120-C2-1-R$$9info:eu-repo/grantAgreement/ES/MICINN/FJC-2020-046181-I$$9info:eu-repo/grantAgreement/ES/MICINN/PTA2020-018510-I/AEI/10.13039/501100011033$$9info:eu-repo/grantAgreement/ES/MINECO/IJC-2019-039192-I
000118733 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000118733 590__ $$a7.3$$b2022
000118733 592__ $$a2.022$$b2022
000118733 591__ $$aIMMUNOLOGY$$b35 / 161 = 0.217$$c2022$$dQ1$$eT1
000118733 593__ $$aImmunology and Allergy$$c2022$$dQ1
000118733 593__ $$aImmunology$$c2022$$dQ1
000118733 594__ $$a9.4$$b2022
000118733 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000118733 700__ $$aPesini, Cecilia
000118733 700__ $$0(orcid)0000-0002-1861-5981$$aSantiago, Llipsy
000118733 700__ $$aHidalgo, Sandra
000118733 700__ $$aCalvo-Pérez, Adanays
000118733 700__ $$aOñate, Carmen
000118733 700__ $$aAndrés Tovar, A.
000118733 700__ $$aGarzón-Tituaña, Mar
000118733 700__ $$aUranga-Murillo, Iratxe
000118733 700__ $$0(orcid)0000-0002-9730-2210$$aArias, Maykel A.
000118733 700__ $$aGalvez, Eva M.
000118733 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000118733 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000118733 773__ $$g13 (2022), 896228 [14 pp.]$$pFront. immunol.$$tFrontiers in Immunology$$x1664-3224
000118733 8564_ $$s2127205$$uhttps://zaguan.unizar.es/record/118733/files/texto_completo.pdf$$yVersión publicada
000118733 8564_ $$s2528473$$uhttps://zaguan.unizar.es/record/118733/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000118733 909CO $$ooai:zaguan.unizar.es:118733$$particulos$$pdriver
000118733 951__ $$a2024-03-18-16:30:08
000118733 980__ $$aARTICLE